Clinical Trial

γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant

Name: γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant — clinical trial record (NCT07123662)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Withdrawn Early Phase 1

View on ClinicalTrials.gov →

Why the trial stopped

Due to corporate strategic adjustment.

Summary

This is a prospective, double-arm, single-center, randomized controlled single-blind clinical study

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-08-08.

Status change: Not Yet Recruiting → Withdrawn 2026-05-26

Trial Details

NCT Number	NCT07123662
Lead Sponsor	Guangzhou Bio-gene Technology Co., Ltd
Conditions	Leukemia, Myeloid, Acute
Start Date	2025-09-01
Primary Completion	2028-05-30 (estimated)
Study Completion	2028-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-28